Prospective Cohort Study of the Risk of Recurrent Atrial Fibrillation After Radiofrequency Ablation

Last updated: February 19, 2024
Sponsor: Peking University Third Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cardiac Disease

Chest Pain

Atrial Fibrillation

Treatment

After radiofrequency ablation of atrial fibrillation

Clinical Study ID

NCT05638841
2022-653-01
  • Ages > 18
  • All Genders

Study Summary

In this study, the continuous inclusion of atrial fibrillation patients treated by catheter ablation in the Department of Cardiology, Peking University Third Hospital, through the collection of clinical data and outpatient follow-up, to explore the risk factors of atrial fibrillation recurrence after catheter ablation and the influencing factors of major clinical events in atrial fibrillation patients, and further guide the management mode of atrial fibrillation patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

    1. Age > 18
    1. ECG or holter electrocardiogram confirmed atrial fibrillation

Exclusion

Exclusion Criteria:

    1. Hematological diseases, autoimmune diseases and malignant tumors
    1. Immobility caused by hemiplegia or severe trauma
    1. The expected survival time is less than 2 years
    1. Poor compliance and high risk of expected loss of follow-up
    1. Disorders of consciousness or Alzheimer's disease

Study Design

Total Participants: 300
Treatment Group(s): 1
Primary Treatment: After radiofrequency ablation of atrial fibrillation
Phase:
Study Start date:
January 01, 2023
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • Peking-University-Third-Hospital

    Beijing,
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.